Barclays
LXRX icon

Barclays’s Lexicon Pharmaceuticals LXRX Stock Holding History

Barclays’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,000
Closed -$17K – 7106
2019
Q1 		$17K Buy
+3,000
New +$18.2K ﹤0.01% 6411
2018
Q1 		– Sell
-6,800
Closed -$67K – 7214
2017
Q4 		$67K Buy
+6,800
New +$70.7K ﹤0.01% 5547
2016
Q3 		– Sell
-259,000
Closed -$3.72M – 6715
2016
Q2 		$3.72M Buy
+259,000
New +$3.51M ﹤0.01% 1522
2016
Q1 		– Sell
-408,400
Closed -$5.31M – 6309
2015
Q4 		$5.31M Buy
+408,400
New +$5.02M 0.01% 1273

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Barclays's LXRX Position: Q2 2026 in Review

Barclays increased its Lexicon Pharmaceuticals (LXRX) stake by 267% in Q2 2026, buying an estimated $549K and bringing the position to 387,483 shares worth $930K. The position accounts for ﹤0.01% of the portfolio, ranked #2836.

Barclays first reported a position in LXRX in Q2 2013 and has held it in 53 quarters since. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Barclays held 387,483 shares of Lexicon Pharmaceuticals worth $930K as of Q2 2026.
  • Barclays bought 281,996 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $549K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2836 holding.
  • Barclays first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.